October 4, 2013
Mundipharma K.K., which is specialized in the oncology field, announced on October 1 that it has initiated a clinical study of its injectable formulation of pralatrexate as an investigational treatment for peripheral T-cell lymphoma (PTCL）for Japanese patients with relapsed or...read more